| scholarly article | Q13442814 |
| P356 | DOI | 10.2147/OPTH.S175065 |
| P953 | full work available at URL | https://www.dovepress.com/a-phase-iiiii-randomized-double-masked-vehicle-controlled-dose-ranging-peer-reviewed-article-OPTH |
| P932 | PMC publication ID | 6174300 |
| P698 | PubMed publication ID | 30323548 |
| P50 | author | Sidney Weiss | Q57095093 |
| P2093 | author name string | Joseph Tauber | |
| Barry A Schechter | |||
| Robert Smyth-Medina | |||
| Melissa M Toyos | |||
| Jason Bacharach | |||
| Jodi I Luchs | |||
| P2860 | cites work | Controlled ocular drug delivery with nanomicelles | Q27012087 |
| Prevalence of dry eye syndrome among US women | Q28196875 | ||
| Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A | Q28316169 | ||
| Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies | Q33720070 | ||
| Aging and dry eye disease | Q34273593 | ||
| Dry eye as a mucosal autoimmune disease | Q34647761 | ||
| TFOS DEWS II pathophysiology report | Q38652987 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
| Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts | Q39185845 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. | Q40948258 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| The Relationship between Habitual Patient-Reported Symptoms and Clinical Signs among Patients with Dry Eye of Varying Severity | Q44631963 | ||
| Antiinflammatory therapy for dry eye. | Q44763839 | ||
| Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. | Q53620228 | ||
| A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. | Q54222666 | ||
| Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes | Q73180482 | ||
| Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine | Q77729873 | ||
| Development and validation of a short global dry eye symptom index | Q79657699 | ||
| Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eyes | Q81357274 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P2507 | corrigendum / erratum | Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] | Q60302035 |
| Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] | Q61810142 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 1921-1929 | |
| P577 | publication date | 2018-10-02 | |
| P1433 | published in | Clinical Ophthalmology | Q5133782 |
| P1476 | title | A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease | |
| P478 | volume | 12 |
| Q89939043 | A Review of Topical Cyclosporine A Formulations-A Disease-Modifying Agent for Keratoconjunctivitis Sicca |
| Q92442286 | Advances in dry eye disease treatment |
| Q91885064 | Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies |
| Q89536542 | Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies |
| Q92246579 | Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits |
| Q91905513 | Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease |
| Q60302035 | Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] |
| Q61810142 | Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] |
Search more.